• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Active Biotech

5.83 SEK

-4.35 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-4.35 %
-17.30 %
+37.18 %
+26.74 %
+29.56 %
-61.97 %
-77.11 %
-87.11 %
-98.59 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Read more
Market cap
153.68M SEK
Turnover
255.71K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

11.2
2027

Annual report '26

Regulatory press release5/28/2026, 6:30 AM

Active Biotech announces timetable for reverse share split

Active Biotech
Regulatory press release5/20/2026, 4:30 PM

Annual General Meeting of Active Biotech AB

Active Biotech
Press release5/13/2026, 9:30 AM

European regulatory approval obtained to resume enrolment in the HOVON 172 MF study evaluating tasquinimod in myelofibrosis and conducted in collaboration between Active Biotech, Oncode and HOVON

Active Biotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/8/2026, 8:14 AM

Redeye: Active Biotech (Q1 Review): Intensified Focus on Business Development

Active Biotech
Regulatory press release5/7/2026, 6:30 AM

Active Biotech Interim Report Q1 2026

Active Biotech
Press release4/20/2026, 9:30 AM

Active Biotech publishes results from the LION study on ocular absorption and distribution of laquinimod in the eye

Active Biotech
Regulatory press release4/17/2026, 12:30 PM

NOTICE OF ANNUAL GENERAL MEETING

Active Biotech
Regulatory press release4/1/2026, 7:30 AM

Annual Report 2025 Active Biotech AB (publ)

Active Biotech
Press release2/13/2026, 12:08 PM

Redeye: Active Biotech (Q4 Review): Tasqinimod Recruiting Again

Active Biotech
Regulatory press release2/12/2026, 7:30 AM

Active Biotech Year End Report 2025

Active Biotech
Press release2/10/2026, 10:30 AM

Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis

Active Biotech
Regulatory press release1/30/2026, 10:30 AM

Number of shares and votes in Active Biotech

Active Biotech
Regulatory press release1/21/2026, 3:15 PM

Active Biotech's nomination committee appointed

Active Biotech
Regulatory press release12/10/2025, 7:00 PM

Active Biotech announces outcome in the rights issue

Active Biotech
Press release11/25/2025, 9:00 AM

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Active Biotech
Regulatory press release11/25/2025, 7:30 AM

The subscription period in Active Biotech’s rights issue begins today

Active Biotech
Press release11/24/2025, 8:30 AM

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Active Biotech
Regulatory press release11/20/2025, 2:45 PM

Active Biotech publishes information document regarding rights issue

Active Biotech
Regulatory press release11/19/2025, 11:00 AM

Extraordinary General Meeting of Active Biotech AB

Active Biotech
Press release11/10/2025, 8:45 AM

Redeye: Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027

Active Biotech